VPC-18005
VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain, and disrupts the ERG binding to DNA. VPC-18005 is a potent inhibitor of luciferase activity[1].
Product Specifications
CAS Number
2242480-48-2
UNSPSC
12352005
Target
DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vpc-18005.html
Purity
99.80
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(O)CC(S/C(N1)=N\N=C/C2=CC=C(C(C)C)C=C2)C1=O
Molecular Formula
C15H17N3O3S
Molecular Weight
319.38
References & Citations
[1]Miriam S Butler, et al. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget. 2017 Jun 27;8 (26) :42438-42454.|[2]Haneen Amawi, et al. The use of zebrafish model in prostate cancer therapeutic development and discovery. Cancer Chemother Pharmacol. 2021 Mar;87 (3) :311-325.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
130847 100 µg
PAK6 (Serine/Threonine-protein Kinase PAK 6, PAK-5, p21-activated Kinase 6, PAK-6, PAK5)
Sign In for Pricing
View Details 
